Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1

• Autorzy: Wesolowska O.
• Języki publikacji: EN

Abstrakty

EN

Multidrug resistance (MDR) of cancer cells poses a serious obstacle to successful chemotherapy. The overexpression of multispecific ATP-binding cassette transporters appears to be the main mechanism of MDR. A search for MDR-reversing agents able to sensitize resistant cells to chemotherapy is ongoing in the hope of their possible clinical use. Studies of MDR modulators, although they have not produced clinically beneficial effects yet, may greatly enrich our knowledge about MDR transporters, their specificity and mechanism of action, especially substrate and/or inhibitor recognition. In the present review, interactions of three groups of modulators: phenothiazines, flavonoids and stilbenes with both P-glycoprotein and MRP1 are discussed. Each group of compounds is likely to interact with the MDR transporters by a different mechanism. Phenothiazines probably interact with drug binding sites, but they also could indirectly affect the transporter's activity by perturbing lipid bilayers. Flavonoids mainly interact with ABC proteins within their nucleotide-binding domains, though the more hydrophobic flavonoids may bind to regions within transmembrane domains. The possible mechanism of MDR reversal by stilbenes may result from their direct interaction with the transporter (possibly within substrate recognition sites) but some indirect effects such as stilbene-induced changes in gene expression pattern and in apoptotic pathways should also be considered. Literature data as well as some of our recent results are discussed. Special emphasis is put on cases when the interactions of a given compound with both P-glycoprotein and MRP1 have been studied simultaneously.

Słowa kluczowe

EN

interaction; phenothiazine; stilbene; flavonoids; multidrug resistance; P-glycoprotein; chlorpromazine; glutathione; anticancer drug; structure-activity relationship; thioridazine; trifluoperazine; transmembrane domain; chemotherapy; tumour; cancer cell

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2011
• Tom: 58
• Numer: 4
• Opis fizyczny: p.433-448,fig.,ref.

Twórcy

autor

Wesolowska O.

• Department of Biophysics, Wroclaw Medical University, Wroclaw, Poland

Bibliografia

• Akiyama S, Cornwell MM, Kuwano M, Pastan I, Gottesman MM (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144-147. 
• Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722. 
• Alvarez AI, Real R, Pérez M, Mendoza G, Prieto JG, Merino G (2010) Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 99: 598-617. 
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398. 
• Ambudkar SV, Kim IW, Sauna ZE (2006) The power of the pump: Mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27: 392-400. 
• Ayesh S, Shao YM, Stein WD (1996) Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316: 8-18. 
• Barbieri F, Alama A, Tasso B, Boido V, Bruzzo C, Sparatore F (2003) Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells. Invest New Drugs 21: 413-420. 
• Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506. 
• Bebawy M, Morris MB, Roufogalis BD (2001) Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer 85: 1998-2003. 
• Beck WT (1984) Cellular pharmacology of Vinca alkaloid resistance and its circumvention. Adv Enzyme Regul 22: 207-227. 
• Bisi A, Meli M, Gobbi S, Rampa A, Tolomeo M, Dusonchet L (2008) Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives. Bioorg Med Chem 16: 6474-6482. 
• Bobrowska-Hägerstrand M, Wróbel A, Mrówczyńska L, Söderström T, Shirataki Y, Motohashi N, Molnár J, Michalak K, Hägerstrand H (2003) Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol Res 13: 463-469. 
• Bobrowska-Hägerstrand M, Lillås M, Mrówczyñska L, Wróbel A, Shirataki Y, Motohashi N, Hägerstrand H (2006) Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res 26: 2081-2084. 
• Boccard J, Bajot F, Di Pietro A, Rudaz S, Boumendjel A, Nicolle E, Carrupt PA (2009) A 3D linear solvation energy model to quantify the affinity of flavonoid derivatives toward P-glycoprotein. Eur J Pharm Sci 36: 254-264. 
• Borst P, Zelcer N, van de Wetering K, Poolman B (2006) On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett 580: 1085-1093. 
• Boumendjel A, Di Pietro A, Dumontet C, Barron D (2002) Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev 22: 512-529. 
• Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea TI, Cruciani G (2011) A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 54: 1740-1751. 
• Callaghan R, Higgins CF (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71: 294-299. 
• Campbell JD, Koike K, Moreau C, Sansom MS, Deeley RG, Cole SP (2004) Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). J Biol Chem 279: 463-468. 
• Castro AF, Altenberg GA (1997) Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53: 89-93. 
• Chan KF, Zhao Y, Burkett BA, Wong IL, Chow LM, Chan TH (2006) Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells. J Med Chem 49: 6742-6759. 
• Chieli E, Romiti N, Cervelli F, Tongiani R (1995) Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 57: 1741-1751. 
• Choi CH, Kim JH, Kim SH (2004) Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun 320: 672-679. 
• Choi JS, Choi BC, Kang KW (2009) Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie 64: 49-52. 
• Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25: 231-259. 
• Chung SY, Sung MK, Kim NH, Jang JO, Go EJ, Lee HJ (2005) Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 28: 823-828. 
• Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654. 
• Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95: 9831-9836. 
• Critchfield JW, Welsh CJ, Phang JM, Yeh GC (1994) Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437-1445. 
• Crowley E, Callaghan R (2010) Multidrug efflux pumps: drug binding - gates or cavity? FEBS J 277: 530-539. 
• Crowley E, McDevitt CA, Callaghan R (2010) Generating inhibitors of P-glycoprotein: where to, now? Methods Mol Biol 596: 405-432. 
• De Vincenzo R, Scambia G, Benedetti Panici P, Fattorossi A, Bonanno G, Ferlini C, Isola G, Pernisco S, Mancuso S (1996) Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 68: 340-348. 
• Dean M (2005) The genetics of ATP-binding cassette transporters. Methods Enzymol 400: 409-429. 
• Dearden JC, Al-Noobi A, Scott AC, Thomson SA (2003) QSAR studies on P-glycoprotein-regulated multidrug resistance and on its reversal by phenothiazines. SAR QSAR Environ Res 14: 447-454. 
• Deeley RG, Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580: 1103-1111. 
• Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94: 10594-10599. 
• Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, de Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, McIntosh DB, Goffeau A, Castanys S, Gamarro F, Barron D (2002) Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci 59: 307-322. 
• Doualla-Bell Kotto Maka F, Breuiller M, Leroy MJ, Josserand S, Ferre F (1990) Sensitivity of the human myometrial adenylate cyclase to calcium and calmodulin. Gynecol Obstet Invest 30: 169-173. 
• Dzubák P, Hajdúch M, Gazák R, Svobodová A, Psotová J, Walterová D, Sedmera P, Kren V (2006) New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem 14: 3793-3810. 
• Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83: 375-383. 
• Eytan GD, Regev R, Oren G, Assaraf YG (1996) The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 271: 12897-12902. 
• Fabris S, Momo F, Ravagnan G, Stevanato R (2008) Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes. Biophys Chem 135: 76-83. 
• Faustino RS, Sobrattee S, Edel AL, Pierce GN (2003) Comparative analysis of the phenolic content of selected Chilean, Canadian and American Merlot red wines. Mol Cell Biochem 249: 11-19. 
• Ferreira MJ, Duarte N, Gyemant N, Radics R, Cherepnev G, Varga A, Molnar J (2006) Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res 26: 3541-3546. 
• Fojo A, Hamilton TC, Young RC, Ozols RF (1987) Multidrug resistance in ovarian cancer. Cancer 60: 2075-2080. 
• Font J, Marino A, Ravelingien N, Dehaye JP, Trueba M, Macarulla JM (1990) Calcium-activated, phospholipid-dependent protein kinase activity in calf platelets. Rev Esp Fisiol 46: 325-330. 
• Ford JM, Prozialeck WC, Hait WN (1989) Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115. 
• Fromm MF (2000) P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38: 69-74. 
• Ganapathi R, Grabowski D, Rouse W, Riegler F (1984) Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. Cancer Res 44: 5056-5061. 
• Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, Ganeshaguru K (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89: 782-790. 
• Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427. 
• Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610-617. 
• Gutmann DA, Ward A, Urbatsch IL, Chang G, van Veen HW (2010) Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends Biochem Sci 35: 36-42. 
• Gyemant N, Tanaka M, Antus S, Hohmann J, Csuka O, Mandoky L, Molnar J (2005) In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In Vivo 19: 367-374. 
• Harborne JB, Williams CA (2000) Advances in flavonoid research since 1992. Phytochemistry 55: 481-504. 
• Hendrich AB, Wesolowska O, Michalak K (2001) Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim Biophys Acta 1510: 414-425. 
• Hendrich AB, Michalak K. (2003) Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr Drug Targets 4: 23-30. 
• Hendrich AB, Wesolowska O, Motohashi N, Molnar J, Michalak K (2003a) New phenothiazine-type multidrug resistance modifiers: anti-MDR activity versus membrane perturbing potency. Biochem Biophys Res Commun 304: 260-265. 
• Hendrich AB, Wesolowska O, Pola A, Motohashi N, Molnar J, Michalak K (2003b) Neither lipophilicity nor membrane-perturbing potency of phenothiazine maleates correlate with the ability to inhibit P-glycoprotein transport activity. Mol Membr Biol 20: 53-60. 
• Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757. 
• Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359-376. 
• Hooijberg JH, Broxterman HJ, Scheffer GL, Vrasdonk C, Heijn M, de Jong MC, Scheper RJ, Lankelma J, Pinedo HM (1999) Potent interaction of flavopiridol with MRP1. Br J Cancer 81: 269-276. 
• Jodoin J, Demeule M, Beliveau R (2002) Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 1542: 149-159. 
• Johnson JD, Wittenauer LA (1983) A fluorescent calmodulin that reports the binding of hydrophobic inhibitory ligands. Biochem J 211: 473-479. 
• Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162. 
• Kane SE (1996) Multidrug resistance of cancer cells. Adv Drug Res 28: 181-252.
• Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y (2007) Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol 60: 789-797. 
• Kaye SB (1988) The multidrug resistance phenotype. Br J Cancer 58: 691-694. 
• Keppler D, Leier I, Jedlitschky G (1997) Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378: 787-791. 
• Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28: 2274-2278. 
• Kitagawa S (2006) Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol Pharm Bull 29: 1-6. 
• Konya A, Andor A, Satorhelyi P, Nemeth K, Kurucz I (2006) Inhibition of the MDR1 transporter by new phenothiazine derivatives. Biochem Biophys Res Commun 346: 45-50. 
• Kothandan G, Gadhe CG, Madhavan T, Choi CH, Cho SJ (2011) Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of P-glycoprotein targeting the nucleotide binding domain. Eur J Med Chem 46: 4078-4088. 
• Kweon SH, Song JH, Kim TS (2010) Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104-110. 
• Lage H (2003) ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199. 
• Lage H (2008) An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 65: 3145-3167. 
• Lania-Pietrzak B, Michalak K, Hendrich AB, Mosiadz D, Grynkiewicz G, Motohashi N, Shirataki Y (2005) Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids. Life Sci 77: 1879-1891. 
• Lee CH (2010) Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 596: 325-340. 
• Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269: 27807-27810. 
• Leite DF, Echevarria-Lima J, Salgado LT, Capella MA, Calixto JB, Rumjanek VM (2006) In vivo and in vitro modulation of MDR molecules in murine thymocytes. Int Immunopharmacol 6: 204-215. 
• Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3: 1652-1659. 
• Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SP (2001) Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59: 1171-1180. 
• Leslie EM, Deeley RG, Cole SP (2003) Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 31: 11-15. 
• Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216-237. 
• Liu R, Sharom FJ (1996) Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35: 11865-11873. 
• Liu R, Siemiarczuk A, Sharom FJ (2000) Intrinsic fluorescence of the P-glycoprotein multidrug transporter: sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry 39: 14927-14938. 
• Loe DW, Almquist KC, Deeley RG, Cole SP (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682. 
• Loe DW, Deeley RG, Cole SP (1998) Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58: 5130-5136. 
• Loe DW, Deeley RG, Cole SP (2000a) Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293: 530-538. 
• Loe DW, Oleschuk CJ, Deeley RG, Cole SP (2000b) Structure-activity studies of verapamil analogs that modulate transport of leukotriene C4 and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275: 795-803. 
• Loo TW, Bartlett MC, Clarke DM (2003) Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278: 39706-39710. 
• Lugo MR, Sharom FJ (2005) Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 44: 643-655. 
• Mao Q, Leslie EM, Deeley RG, Cole SP (1999) ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochim Biophys Acta 1461: 69-82. 
• Marbeuf-Gueye C, Ettori D, Priebe W, Kozlowski H, Garnier-Suillerot A (1999) Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Biochim Biophys Acta 1450: 374-384. 
• Marques LO, Lima MS, Soares BG (2004) Trifluoperazine for schizophrenia. Cochrane Database Syst Rev CD003545. 
• Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58: 624-632. 
• Mavel S, Dikic B, Palakas S, Emond P, Greguric I, de Gracia AG, Mattner F, Garrigos M, Guilloteau D, Katsifis A (2006) Synthesis and biological evaluation of a series of flavone derivatives as potential radioligands for imaging the multidrug resistance-associated protein 1 (ABCC1/MRP1). Bioorg Med Chem 14: 1599-1607. 
• McDevitt CA, Callaghan R (2007) How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113: 429-441. 
• Michalak K, Wesolowska O, Motohashi N, Molnar J, Hendrich AB (2006) Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr Drug Targets 7: 1095-1105. 
• Michalak K, Wesolowska O, Motohashi N, Hendrich AB (2007) The role of the membrane actions of phenothiazines and flavonoids as functional modulators. Top Heterocycl Chem 8: 223 -302.
• Molnar J, Molnar A, Mucsi I, Pinter O, Nagy B, Varga A, Motohashi N (2003) Reversal of multidrug resistance in mouse lymphoma cells by phenothiazines. In Vivo 17: 145-149. 
• Molnar J, Engi H, Hohmann J, Molnar P, Deli J, Wesolowska O, Michalak K, Wang Q (2010) Reversal of multidrug resistance by natural substances from plants. Curr Top Med Chem 10: 1757-1768. 
• Morris ME, Zhang S (2006) Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. Life Sci 78: 2116-2130. 
• Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C (2007) Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 48: 708-715. 
• Motohashi N, Kurihara T, Kawase M, Hever A, Tanaka M, Szabo D, Nacsa J, Yamanaka W, Kerim A, Molnar J (1997) Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines. Anticancer Res 17: 3537-3543. 
• Na HK, Surh YJ (2006) Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol Nutr Food Res 50: 152-159. 
• Nabekura T, Kamiyama S, Kitagawa S (2005) Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 327: 866-870. 
• Nabekura T, Yamaki T, Kitagawa S (2008) Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur J Pharmacol 600: 45-49. 
• Nguyen H, Zhang S, Morris ME (2003) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92: 250-257. 
• Ohtani H, Ikegawa T, Honda Y, Kohyama N, Morimoto S, Shoyama Y, Juichi M, Naito M, Tsuruo T, Sawada Y (2007) Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharm Res 24: 1936-1943. 
• Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S (2010) Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 33: 255-259. 
• Pajeva IK, Wiese M, Cordes HP, Seydel JK (1996) Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability. J Cancer Res Clin Oncol 122: 27-40. 
• Pajeva IK, Wiese M (1998) Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem 41: 1815-1826. 
• Pajeva IK, Globisch C, Wiese M (2009) Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. ChemMedChem 4: 1883-1896. 
• Patanasethanont D, Nagai J, Matsuura C, Fukui K, Sutthanut K, Sripanidkulchai BO, Yumoto R, Takano M (2007a) Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur J Pharmacol 566: 67-74. 
• Patanasethanont D, Nagai J, Yumoto R, Murakami T, Sutthanut K, Sripanidkulchai BO, Yenjai C, Takano M (2007b) Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function. J Pharm Sci 96: 223-233. 
• Payen LF, Gao M, Westlake CJ, Cole SP, Deeley RG (2003) Role of carboxylate residues adjacent to the conserved core Walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1). J Biol Chem 278: 38537-38547. 
• Peroutka SJ, Synder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518-1522. 
• Phang JM, Poore CM, Lopaczynska J, Yeh GC (1993) Flavonol-stimulated efflux of 7,12-dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res 53: 5977-5981. 
• Pirola L, Frojdo S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323-332. 
• Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA, Burke MD (2002) The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778. 
• Pulaski L, Jedlitschky G, Leier I, Buchholz U, Keppler D (1996) Identification of the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of erythrocytes. Eur J Biochem 241: 644-648. 
• Quan F, Pan C, Ma Q, Zhang S, Yan L (2008) Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother 62: 622-629. 
• Raderer M, Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72: 3553-3563. 
• Ramu A, Ramu N (1992) Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 30: 165-173. 
• Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265: 3975-3980. 
• Rosenberg MF, Oleschuk CJ, Wu P, Mao Q, Deeley RG, Cole SP, Ford RC (2010) Structure of a human multidrug transporter in an inward-facing conformation. J Struct Biol 170: 540-547. 
• Roupe KA, Remsberg CM, Yanez JA, Davies NM (2006) Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 1: 81-101. 
• Rychlik B, Balcerczyk A, Klimczak A, Bartosz G (2003) The role of multidrug resistance protein 1 (MRP1) in transport of fluorescent anions across the human erythrocyte membrane. J Membr Biol 193: 79-90. 
• Safa AR, Agresti M, Bryk D, Tamai I (1994) N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells. Biochemistry 33: 256-265. 
• Safa AR (1998) Photoaffinity labels for characterizing drug interaction sites of P-glycoprotein. Methods Enzymol 292: 289-307. 
• Sauna ZE, Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 97: 2515-2520. 
• Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130: 2073S-2285S. 
• Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8: 161-170. 
• Schmidt M, Teitge M, Castillo ME, Brandt T, Dobner B, Langner A (2008) Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents. Arch Pharm 341: 624-638. 
• Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251: 252-261. 
• Seelig A, Blatter XL, Wohnsland F (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther 38: 111-121. 
• Senior AE, Al-Shawi MK, Urbatsch IL (1995) The catalytic cycle of P-glycoprotein. FEBS Lett 377: 285-289. 
• Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250: 130-137. 
• Shapiro AB, Fox K, Lam P, Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259: 841-850. 
• Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127. 
• Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH (1998) Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 56: 719-727. 
• Sheu MT, Liou YB, Kao YH, Lin YK, Ho HO (2010) A quantitative structure-activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. Chem Pharm Bull 58: 1187-1194. 
• Signorelli P, Ghidoni R (2005) Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16: 449-466. 
• Skovsgaard T, Nielsen D, Maare C, Wassermann K (1994) Cellular resistance to cancer chemotherapy. Int Rev Cytol 156: 77-157. 
• Stouch TR, Gudmundsson O (2002) Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54: 315-328. 
• Syed SK, Christopherson RI, Roufogalis BD (1998) Reversal of vinblastine transport by chlorpromazine in membrane vesicles from multidrug-resistant human CCRF-CEM leukaemia cells. Br J Cancer 78: 321-327. 
• Szabo D, Szabo GJ, Ocsovszki I, Aszalos A, Molnar J (1999) Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119. 
• Tawari NR, Bag S, Degani MS (2008) Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. J Mol Model 14: 911-921. 
• Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 7: 893-909. 
• Tian X, Yang X, Wang K (2006) The efflux of flavonoids morin, isorhamnetin-3-O-rutinoside and diosmetin-7-O-beta-D-xylopyranosyl-(1-6)-beta-D-glucopyranoside in the human intestinal cell line caco-2. Pharm Res 23: 1721-1728. 
• Trompier D, Baubichon-Cortay H, Chang XB, Maitrejean M, Barron D, Riordon JR, Di Pietro A (2003) Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 60: 2164-2177. 
• Tsakovska IM (2003) QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells. Bioorg Med Chem 11: 2889-2899. 
• Tsakovska I, Pajeva I (2006) Phenothiazines and structurally related compounds as modulators of cancer multidrug resistance. Curr Drug Targets 7: 1123-1134. 
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733. 
• van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, Cnubben NH (2004) Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 67: 1607-1617. 
• van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, Bladeren PJ, Rietjens IM, Cnubben NH (2005) Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 69: 699-708. 
• Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J, Broxterman HJ (1993) Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939-946. 
• Versantvoort CH, Rhodes T, Twentyman PR (1996) Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer 74: 1949-1954. 
• Wang EJ, Barecki-Roach M, Johnson WW (2002) Elevation of P-glycoprotein function by a catechin in green tea. Biochem Biophys Res Commun 297: 412-418. 
• Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28: 203-228. 
• Wang Y, Cao J, Zeng S (2005) Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 57: 751-758. 
• Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Devane CL (2006) Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 187: 415-423. 
• Wesolowska O, Molnar J, Motohashi N, Michalak K (2002) Inhibition of P-glycoprotein transport function by N-acylphenothiazines. Anticancer Res 22: 2863-2867. 
• Wesolowska O, Mosiadz D, Motohashi N, Kawase M, Michalak K (2005a) Phenothiazine maleates stimulate MRP1 transport activity in human erythrocytes. Biochim Biophys Acta 1720: 52-58. 
• Wesolowska O, Paprocka M, Kozlak J, Motohashi N, Dus D, Michalak K (2005b) Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res 25: 383-389. 
• Wesolowska O, Wisniewski J, Duarte N, Ferreira MJ, Michalak K (2007) Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res 27: 4127-4133. 
• Wesolowska O, Molnar J, Ocsovszki I, Michalak K (2009a) Differential effect of phenothiazines on MRP1 and P-glycoprotein activity. In Vivo 23: 943-947. 
• Wesolowska O, Hendrich AB, Lania-Pietrzak B, Wisniewski J, Molnar J, Ocsovszki I, Michalak K (2009b) Perturbation of the lipid phase of a membrane is not involved in the modulation of MRP1 transport activity by flavonoids. Cell Mol Biol Lett 14: 199-221. 
• Wesolowska O, Kuzdzal M, Strancar J, Michalak K (2009c) Interaction of the chemopreventive agent resveratrol and its metabolite, piceatannol, with model membranes. Biochim Biophys Acta 1788: 1851-1860. 
• Wesolowska O, Wisniewski J, Sroda K, Krawczenko A, Bielawska-Pohl A, Paprocka M, Dus D, Michalak K (2010a) 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. Eur J Pharmacol 644: 32-40. 
• Wesolowska O, Wisniewski J, Bielawska-Pohl A, Paprocka M, Duarte N, Ferreira MJ, Dus D, Michalak K (2010b) Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells. Anticancer Res 30: 4587-4593. 
• Wesolowska O, Michalak K, Hendrich AB (2011) Direct visualization of phase separation induced by phenothiazine-type antipsychotic drugs in model lipid membranes. Mol Membr Biol 28: 103-114. 
• Wong IL, Chan KF, Tsang KH, Lam CY, Zhao Y, Chan TH, Chow LM (2009) Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J Med Chem 52: 5311-5322. 
• Wu CP, Calcagno AM, Hladky SB, Ambudkar SV, Barrand MA (2005) Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J 272: 4725-4740. 
• Yang R, Cui L, Hou YX, Riordan JR, Chang XB (2003) ATP binding to the first nucleotide binding domain of multidrug resistance-associated protein plays a regulatory role at low nucleotide concentration, whereas ATP hydrolysis at the second plays a dominant role in ATP-dependent leukotriene C4 transport. J Biol Chem 278: 30764-30771. 
• Yang R, McBride A, Hou Y, Goldberg A, Chang X (2005) Nucleotide dissociation from NBD1 promotes solute transport by MRP1. Biochim Biophys Acta 1668: 248-261. 
• Yu R, Jiao JJ, Duh JL, Gudehithlu K, Tan TH, Kong AN (1997) Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis 18: 451-456. 
• Zamora JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462. 
• Zhang S, Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304: 1258-1267. 
• Zhang S, Sagawa K, Arnold RD, Tseng E, Wang X, Morris ME (2010) Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci 99: 430-441.